Keywords
Gene mutation
Future risks
How to Cite
Abstract
Introduction: This study explores the importance of genetic and epidemiological biomarkers in the identification and classification of central nervous system (CNS) tumors, focusing on mutations in the IDH1, IDH2 genes, and methylation of the MGMT gene promoter, which play crucial roles in the prognosis and treatment response of gliomas. Objective: To integrate the analysis of these biomarkers with epidemiological risk factors to support the personalization of therapeutic strategies, aiming to create a personalized database in the future. Methodology: The methodology consisted of a systematic literature review following PRISMA guidelines. Searches were conducted in the PubMed and Science Direct databases, covering studies published between 2012 and 2024. After applying inclusion and exclusion criteria, 31 articles were selected for analysis. Results: Mutations in the IDH1 gene, especially the R132H mutation, and MGMT promoter methylation were found to be key determinants in the prognosis and personalized treatment of gliomas. Environmental risk factors, such as prolonged exposure to ionizing radiation and electromagnetic fields, were significantly associated with an increased risk of developing CNS tumors. Discussion: The importance of an integrative approach combining genetic and epidemiological data was highlighted. This integration can allow substantial advances in the diagnosis, prognosis, and personalized treatment of CNS tumors. Conclusion: The study reaffirms the relevance of neurogenetic biomarkers in the personalization of therapeutic strategies and highlights the need for integrative approaches to enhance clinical interventions and improve patient outcomes.
References
Aydemir, E., Arslan, İ.İ., Görkay, A.H. (2023). The Application of Electromagnetic Fields in Cancer. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 21. Advances in Experimental Medicine and Biology(), vol 1450. Springer, Cham. doi: 10.1007/5584_2023_788.
Baldi I, De Graaf L, Bouvier G, Gruber A, Loiseau H, Meryet-Figuiere M, Rousseau S, Fabbro-Peray P, Lebailly P. Occupational exposure to pesticides and central nervous system tumors: results from the CERENAT case-control study. Cancer Causes Control. 2021 Jul;32(7):773-782. doi: 10.1007/s10552-021-01429-x. Epub 2021 Apr 19. PMID: 33876308.
Bray et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer journal for clinicians, Hoboken, v. 68, n. 6, p. 394-424, 2018.
Davis Andrew A. , Gerratana Lorenzo , Mina Marco. Cancer evolution: From biological insights to therapeutic opportunities. Frontiers in Genetics, 13: 2022. doi: 10.3389/fgene.2022.984032
Gakinya S, Mutuiri A, Onyuma T, Cheserem B, Mogere E. Frequency of IDH1 mutation in adult-type diffuse astrocytic gliomas in a tertiary hospital in Kenya. Front Med (Lausanne). 2024 Feb 19;11:1305714. doi: 10.3389/fmed.2024.1305714. PMID: 38444421; PMCID: PMC10913195.
Gomes I, Moreno DA, Dos Reis MB, da Silva LS, Leal LF, Gonçalves GM, Pereira CA, Oliveira MA, de Medeiros Matsushita M, Reis RM. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. J Neurooncol. 2021 Jan;151(2):135-144. doi: 10.1007/s11060-020-03675-6. Epub 2021 Jan 5. PMID: 33400009.
Instituto Nacional do Câncer José Alencar Gomes da Silva. Câncer do sistema nervoso central. Rio de Janeiro, 2020. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/sistema-nervoso-central (Acessado em 12 de Agosto de 2022).
Instituto Nacional do Câncer José Alencar Gomes da Silva. Câncer do sistema nervoso central. Rio de Janeiro, 2022. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/sistema-nervoso-central (Acessado em 08 de fevereiro de 2024).
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012 Jul;3(7):709-22. doi: 10.18632/oncotarget.588. PMID: 22869205; PMCID: PMC3443254.
Jimenez AE, Cicalese KV, Chakravarti S, Porras JL, Azad TD, Jackson CM, Gallia GL, Bettegowda C, Weingart J, Mukherjee D. Social determinants of health and the prediction of 90-day mortality among brain tumor patients. J Neurosurg. 2022 Mar 11:1-9. doi: 10.3171/2022.1.JNS212829. Epub ahead of print. PMID: 35353473.
Kamps R, Brandão RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, Romano A. Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci. 2017 Jan 31;18(2):308. doi: 10.3390/ijms18020308. PMID: 28146134; PMCID: PMC5343844.
Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012 Oct;3(10):1194-203. doi: 10.18632/oncotarget.689. PMID: 23104868; PMCID: PMC3717947.
Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017 Sep 7;170(6):1062-1078. doi: 10.1016/j.cell.2017.08.028. PMID: 28886379; PMCID: PMC5743327.
Lake J, Storm CS, Makarious MB, Bandres-Ciga S. Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells. 2021 Apr 27;10(5):1030. doi: 10.3390/cells10051030. PMID: 33925602; PMCID: PMC8170880.
Lin FML, Bacchi CE, Baracat EC, Carvalho FM. Loss of PTEN expression and AKT activation in HER2-positive breast carcinomas. Rev Bras Ginecol Obstet. 2014 Aug;36(8):340–6. https://doi.org/10.1509/SO100-720320140005034
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231-51.
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 131(6), 803-820.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 2023;389:589–601. doi: 10.1056/NEJMoa2304194.
Nordfors K, Haapasalo J, Afyounian E, Tuominen J, Annala M, Häyrynen S, Karhu R, Helén P, Lohi O, Nykter M, Haapasalo H, Granberg KJ. Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2):a002246. doi: 10.1101/mcs.a002246. Erratum in: Cold Spring Harb Mol Case Stud. 2018 Jun 1;4(3):a003129. doi: 10.1101/mcs.a003129. PMID: 29602769; PMCID: PMC5880256.
Ostrom QT, Adel Fahmideh M, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, Bondy ML. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019 Nov 4;21(11):1357-1375. doi: 10.1093/neuonc/noz123. PMID: 31301133; PMCID: PMC6827837.
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014 Jul;16(7):896-913. doi: 10.1093/neuonc/nou087. PMID: 24842956; PMCID: PMC4057143.
Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of Brain and Other CNS Tumors. Curr Neurol Neurosci Rep. 2021 Nov 24;21(12):68. doi: 10.1007/s11910-021-01152-9. PMID: 34817716; PMCID: PMC8613072.
Sandes, V. dos A., Dantas, RL., Porto, RLS., Reis, FFP., Sousa, DS de., Lima, SO., Marcena, SLS., Reis, FP. A ocorrência de tumores do sistema nervoso central no estado de Sergipe de 2008 a 2017. Pesquisa, Sociedade e Desenvolvimento, v. 9, n. 11, p. e3439119673, 2020. doi: 10.33448/rsd-v9i11.9673.
Seoane J, De Mattos-Arruda L, Le Rhun E, et al. Cerebrospinal fuid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019;30:211–8. https://doi.org/10.1093/annonc/mdy544.
Aydemir E, Arslan İİ, Görkay AH. The Application of Electromagnetic Fields in Cancer. In: Turksen K, editor. Cell Biology and Translational Medicine, Volume 21. Adv Exp Med Biol. 2023;1450:1-12. https://doi.org/10.1007/5584_2023_788
Baldi I, De Graaf L, Bouvier G, Gruber A, Loiseau H, Meryet-Figuiere M, et al. Occupational exposure to pesticides and central nervous system tumors: results from the CERENAT case-control study. Cancer Causes Control. 2021;32(7):773-82. doi: 10.1007/s10552-021-01429-x. PMID: 33876308.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492. PMID: 30207593.
Davis AA, Gerratana L, Mina M. Cancer evolution: From biological insights to therapeutic opportunities. Front Genet. 2022;13:984032. doi: 10.3389/fgene.2022.984032.
Gakinya S, Mutuiri A, Onyuma T, Cheserem B, Mogere E. Frequency of IDH1 mutation in adult-type diffuse astrocytic gliomas in a tertiary hospital in Kenya. Front Med (Lausanne). 2024;11:1305714. doi: 10.3389/fmed.2024.1305714. PMID: 38444421; PMCID: PMC10913195.
Gomes I, Moreno DA, Dos Reis MB, da Silva LS, Leal LF, Gonçalves GM, et al. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. J Neurooncol. 2021;151(2):135-44. doi: 10.1007/s11060-020-03675-6. PMID: 33400009.
Instituto Nacional do Câncer José Alencar Gomes da Silva. Câncer do sistema nervoso central. Rio de Janeiro: INCA; 2020 [cited 2022 Aug 12]. Available from: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/sistema-nervoso-central
Instituto Nacional do Câncer José Alencar Gomes da Silva. Câncer do sistema nervoso central. Rio de Janeiro: INCA; 2022 [cited 2024 Feb 08]. Available from: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/sistema-nervoso-central
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709-22. doi: 10.18632/oncotarget.588. PMID: 22869205; PMCID: PMC3443254.
Jimenez AE, Cicalese KV, Chakravarti S, Porras JL, Azad TD, Jackson CM, et al. Social determinants of health and the prediction of 90-day mortality among brain tumor patients. J Neurosurg. 2022 Mar 11:1-9. doi: 10.3171/2022.1.JNS212829. PMID: 35353473.
Kamps R, Brandão RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, et al. Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci. 2017;18(2):308. doi: 10.3390/ijms18020308. PMID: 28146134; PMCID: PMC5343844.
Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194-203. doi: 10.18632/oncotarget.689. PMID: 23104868; PMCID: PMC3717947.
Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170(6):1062-78. doi: 10.1016/j.cell.2017.08.028. PMID: 28886379; PMCID: PMC5743327.
Lake J, Storm CS, Makarious MB, Bandres-Ciga S. Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells. 2021;10(5):1030. doi: 10.3390/cells10051030. PMID: 33925602; PMCID: PMC8170880.
Lin FML, Bacchi CE, Baracat EC, Carvalho FM. Loss of PTEN expression and AKT activation in HER2-positive breast carcinomas. Rev Bras Ginecol Obstet. 2014;36(8):340–6. doi: 10.1509/SO100-720320140005034.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231-51.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389:589–601. doi: 10.1056/NEJMoa2304194.
Nordfors K, Haapasalo J, Afyounian E, Tuominen J, Annala M, Häyrynen S, et al. Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4(2). doi: 10.1101/mcs.a002246. PMID: 29602769; PMCID: PMC5880256.
Ostrom QT, Adel Fahmideh M, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019;21(11):1357-75. doi: 10.1093/neuonc/noz123. PMID: 31301133; PMCID: PMC6827837.
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014;16(7):896-913. doi: 10.1093/neuonc/nou087. PMID: 24842956; PMCID: PMC4057143.
Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of Brain and Other CNS Tumors. Curr Neurol Neurosci Rep. 2021;21(12):68. doi: 10.1007/s11910-021-01152-9. PMID: 34817716; PMCID: PMC8613072.
Sandes VA, Dantas RL, Porto RLS, Reis FFP, Sousa DS, Lima SO, et al. A ocorrência de tumores do sistema nervoso central no estado de Sergipe de 2008 a 2017. Pesq Soc Desenv. 2020;9(11). doi: 10.33448/rsd-v9i11.9673.
Seoane J, De Mattos-Arruda L, Le Rhun E, et al. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019;30:211-8. doi: 10.1093/annonc/mdy544.
Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20. doi: 10.1002/1878-0261.12155. PMID: 29124875; PMCID: PMC5748484.
Stoyanov GS, Sarraf JS, Matev BK, Dzhenkov DL, Kitanova M, Iliev B, et al. A Comparative Review of Demographics, Incidence, and Epidemiology of Histologically Confirmed Intracranial Tumors in Brazil and Bulgaria. Cureus. 2018 Feb 19;10(2). doi: 10.7759/cureus.2203. PMID: 29682433; PMCID: PMC5908715.
Trevisan FA, Oliveira HF, Tirapelli DPC, Carlotti Junior CG. MicroRNAs - Biogênese, funções e biomarcadores preditivos em glioblastoma. Braz J Oncol. 2017;13:1-9.
Vasconcelos DS, da Silva FP, Quintana LG, Anselmo NP, Othman MA, Liehr T, de Oliveira EH. Numerical aberrations of chromosome 17 and TP53 in brain metastases derived from breast cancer. Genet Mol Res. 2013 Jan 4;12(3):2594-600. doi: 10.4238/2013.January.4.15. PMID: 23315874.
Villalobos A, Wagner A, Marques LB, Clazer B, Reimann Junior ON, Lindner S, et al. Estudo Sobre a Incidência de Tumores no Sistema Nervoso Central e na Calota Craniana em Pacientes Atendidos em Hospital Regional do Planalto Norte Catarinense. J Bras Neurocirur. 2023;34(2):185-93. doi: 10.22290/jbnc.2023.340208.
Weller M, Reifenberger G. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? Curr Opin Neurol. 2020;33(6):701-06. doi: 10.1097/WCO.0000000000000871. PMID: 33177376.
Xiao WZ, Han DH, Wang F, Wang YQ, Zhu YH, Wu YF, et al. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis. Tumour Biol. 2014;35(7):6687-93. doi: 10.1007/s13277-014-1885-1. PMID: 24705863.
Yamanaka R, Hayano A, Kanayama T. Radiation-induced gliomas: a comprehensive review and meta-analysis. Neurosurg Rev. 2018;41:719-31. doi: 10.1007/s10143-016-0786-8.
Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336-46. doi: 10.1056/NEJMoa1508054. PMID: 26580448; PMCID: PMC4734119.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 CARINA TOLEDO SCOPARO BARIONI, Gustavo Machado Pereira, Marianna Boia Ferreira, Chelin Auswaldt Steclan
